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ABSTRACT   We report the case of a 62-year-old woman diagnosed with myasthenia gravis. 
She felt dyspnea and weakness of bilateral upper limbs, followed by left blepharoptosis. 
Pyridostigmine markedly improved her symptoms. But later, blepharoptosis and head drop 
worsened and predonisolone was ineffective. Yet, after intravenous immunoglobulin therapy her 
symptoms markedly improved. However, her head drop worsened at intervals of 25.79 days on 
average. She was administered L-carnitine, and the interval until exacerbation became longer 
(40.67 days on average). This case is interesting because L-carnitine therapy has never been 
reported as therapy for myasthenia gravis. doi：10.11482/KMJ-E43(1)1　(Accepted on December 24, 2016)
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〈Case Report〉
INTRODUCTION
   In myasthenia gravis, neuromuscular transmission 
is  impaired by auto-antibodies against  the 
acetylcholine receptors localized in the synaptic 
membrane of the neuromuscular junction１－３）. 
Clinical features include weakness and fatigability 
of skeletal muscles. We report the case of a patient 
with myasthenia gravis who did not respond to 
therapy with steroids, achieved remission after 
treatment with immunoglobulin, but suffered 
repeated episodes of remission and exacerbation. 
However, L-carnitine prolonged the interval between 
the exacerbation episodes in this patient. 
CASE REPORT
   The patient, a 62-year-old woman, noted weakness 
of the upper limbs; then she started feeling 
shortness of breath and was subjected to several 
tests, including blood tests, chest x-ray, and ECG, 
all of which showed no abnormalities. The patient 
presented 5 days after onset of left blepharoptosis, 
which worsened when she was tired. Besides, when 
she raised her arms, she complained of languor. 
She visited our hospital again, and tensilon test 
was positive for myasthenia gravis. Thus, she 
was admitted on the same day. On admission, her 
neurological signs were bilateral blepharoptosis, 
and left external strabismus. Eye movements were 
normal. Bilateral large pectoral muscles and deltoid 
muscles revealed mild weakness. Muscle strength 
of lower extremities was normal. A blood test 
showed 97,000 platelets /μL, and anti-acetylcholine 
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receptor antibodies were 32 nmol/L (normally 0～
0.2). The chest magnetic resonance imaging (MRI) 
was negative for a thymoma or thymic hyperplasia. 
Repetitive stimulation test showed no obvious 
waning. She was diagnosed with myasthenia gravis 
(myasthenia gravis foundation of America (MGFA) 
Ⅱa, myasthenia gravis-activities of daily living 
(MG-ADL) scale 3). The patient was administered 
pyridostigmine, and as her symptoms improved 
markedly she was discharged from hospital. 
Nevertheless, 2 weeks later she complained of head 
drop, bilateral blepharoptosis, and oppressive feeling 
of posterior neck; she was started on prednisolone. 
But her symptoms showed no improvement. 
Because 199 days after onset she still had bilateral 
blepharoptosis, and head drop all day long, she 
was admitted to our hospital. Although steroid 
pulse therapy (methylprednisolone 1,000mg/day
×3 days) was provided, her symptoms worsened 
(Fig.1A). High-dose intravenous immunoglobulin 
therapy was started (400 mg / kg / day×5 days). 
Her symptoms showed a remarkable improvement 
and she was discharged from hospital. Thereafter, 
while under high-dose intravenous immunoglobulin 
therapy, she attended our hospital every 19-36 
days due to worsening of head drop (25.79 days on 
average). She was started on L-carnitine 1,500 mg/
day on Day 805 after onset, but no prolongation of 
the interval between the episodes of remission and 
exacerbation was observed. The dose of L-carnitine 
was increased to 1,750 mg/day on Day 834, which 
prolonged the interval until exacerbation to 39-42 
days (40.67 days on average) (Fig.1B). The patient 
reported a great improvement of her quality of life. 
Serum concentrations of carnitine before L-carnitine 
administration were 59.9 μmol / L for total 
carnitine (standard value 45-91), 47.0 μmol / L 
for free carnitine (standard value 36-74), and 12.9 
μmol/L for acylcarnitine (standard value 6-23). 
They were all within standard range. Serum anti-
acetylcholine receptor antibodies were 34 nmol/L 
on Day 874 and 26 nmol/L on Day 958.
DISCUSSION
   Carnitine was first found in muscle tissue in 
1905, but its physiological role was unclear for 
many years. Studies reported in the 1950s showed 
that L-carnitine played important roles in fatty 
acid β-oxidation via transportation of long-chain 
fatty acids into the mitochondrial matrix and in 
the control of the mitochondrial acyl coenzyme A 
(CoA) /CoA ratio, which is important for energy 
metabolism in the cells４）. Oyanagi et al. found 
that mitochondrial membrane fatty acid stress was 
suppressed by the coexistence of L-carnitine５）. 
   Mariano et al. tried to administer L-carnitine 
to centenarians with onset of fatigue after even 
slight physical activity. They reported that oral 
administration of L-carnitine produced a reduction 
of total fat mass, increased total muscular mass, 
and facilitated an increased capacity for physical 
and cognitive activity by reducing fatigue and 
improving cognitive functions６）. Eric et al. reported 
that intravenous L-carnitine reduced fatigue, and 
might preserve exercise capacity in hemodialysis 
patients７）.
   As for neurological disorders, there was the 
case of a patient with multiple sclerosis in 
whom L-carnitine was effective. Lebrun et al. 
reported that the degree of fatigue decreased in 
63% of their patients with multiple sclerosis and 
immunosuppressive therapy-induced fatigue, after 
treatment with L-carnitine８）. Because of this report, 
we tried to administer L-carnitine to our patient. A 
major symptom of myasthenia gravis is easy muscle 
fatigability. The increased L-carnitine pool achieved 
in skeletal muscle in our patient probably resulted in 
increased energy metabolism in the mitochondria of 
muscle cells and a longer interval between remission 
and exacerbation, suggesting decreased muscle 
fatigue. Our case is interesting because L-carnitine 
therapy has never been reported as therapy for 
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Fig. 1.　Clinical course
A. From onset to before high-dose intravenous immunoglobulin therapy. 
B. After high-dose intravenous immunoglobulin therapy(IVIg) and L-carnitine administration. While under high-dose intravenous 
immunoglobulin therapy, the patient attended our hospital every 19-36 days due to worsening of head drop (25.79 days on 
average). She was started on L-carnitine 1,500 mg/day on Day 805 after onset, but no prolongation of the interval between the 
episodes of remission and exacerbation was observed. The dose of L-carnitine was increased to 1,750 mg/day on Day 834, which 
prolonged the interval until exacerbation to 39-42 days (40.67 days on average) .
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myasthenia gravis.
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